|
|
Post by compound26 on Jun 15, 2017 9:53:20 GMT -5
Non-Invasive Testing That Works www.healthline.com/diabetesmine/diabetes-tech-display-ada-77th-scientific-sessions#18One of the most exciting things we saw on the expo floor was a company called DiabetOmics out of Oregon, which is poised to soon launch a new non-invasive BG control test and two "point-of-care" diagnostic tools that could change diabetes treatment! The first is Glucema, a saliva test that measures your average glucose readings over the past 1-2 weeks. It's a little stick that collects a drop of saliva and provides an immediate result. It connects to a handheld reader device that records results and can transfer them to mobile devices, and an app that can track results and also the patient's insulin doses and other parameters, and provide "alerts for critical readings and adverse outcomes." TBD on exactly how the app works, but this non-invasive test -- with study results to back its accuracy -- looks pretty exciting! The other two tests, which are also administered right in the clinic or physician's practice with no need to go to a lab, are: Insudex, for early detection of type 1 diabetes and LADA (Latent Autoimmune Diabetes in Adults) -- a USB-stick-sized device that takes a fingerstick blood sample and provides results with 2-5 minutes. Those results show a variety of autobody levels including GAD and C-peptide that indicate T1D. Imagine, all those sophisticated results with just one drop of blood right in your doctor's office! And finally Lumella - a similar test for detection of preeclampsia and gestational diabetes. Seriously, this could do away with the need for the traditional Oral Glucose Tolerance Test (OGTT) that requires drinking disgusting liquid and hanging around in a lab for hours. The company boasts high accuracy: "90% of subjects with a positive Lumella test in the first trimester will test positive with the OGTT at 24-28 weeks gestation." All these are coming to market in early 2018, we're told. |
|
|
|
Post by peppy on Jun 15, 2017 9:56:04 GMT -5
Non-Invasive Testing That Works www.healthline.com/diabetesmine/diabetes-tech-display-ada-77th-scientific-sessions#18One of the most exciting things we saw on the expo floor was a company called DiabetOmics out of Oregon, which is poised to soon launch a new non-invasive BG control test and two "point-of-care" diagnostic tools that could change diabetes treatment! The first is Glucema, a saliva test that measures your average glucose readings over the past 1-2 weeks. It's a little stick that collects a drop of saliva and provides an immediate result. It connects to a handheld reader device that records results and can transfer them to mobile devices, and an app that can track results and also the patient's insulin doses and other parameters, and provide "alerts for critical readings and adverse outcomes." TBD on exactly how the app works, but this non-invasive test -- with study results to back its accuracy -- looks pretty exciting! The other two tests, which are also administered right in the clinic or physician's practice with no need to go to a lab, are: Insudex, for early detection of type 1 diabetes and LADA (Latent Autoimmune Diabetes in Adults) -- a USB-stick-sized device that takes a fingerstick blood sample and provides results with 2-5 minutes. Those results show a variety of autobody levels including GAD and C-peptide that indicate T1D. Imagine, all those sophisticated results with just one drop of blood right in your doctor's office! And finally Lumella - a similar test for detection of preeclampsia and gestational diabetes. Seriously, this could do away with the need for the traditional Oral Glucose Tolerance Test (OGTT) that requires drinking disgusting liquid and hanging around in a lab for hours. The company boasts high accuracy: "90% of subjects with a positive Lumella test in the first trimester will test positive with the OGTT at 24-28 weeks gestation." All these are coming to market in early 2018, we're told. The first is Glucema, a saliva test that measures your average glucose readings over the past 1-2 weeks. Sounds good but no cigar. (not going to cut it.) what did they used to say, close only counts for horseshoes and hand granades.
|
|
|
|
Post by compound26 on Jun 15, 2017 10:05:23 GMT -5
The first is Glucema, a saliva test that measures your average glucose readings over the past 1-2 weeks. It's a little stick that collects a drop of saliva and provides an immediate result. It connects to a handheld reader device that records results and can transfer them to mobile devices, and an app that can track results and also the patient's insulin doses and other parameters, and provide "alerts for critical readings and adverse outcomes." TBD on exactly how the app works, but this non-invasive test -- with study results to back its accuracy -- looks pretty exciting!
-------------------------------------------------------------------------------------------------
My thinking is that if this is cheap and accurate enough, this could really be used to showcase the benefit of Afrezza while a PWD is still titrating Afrezza. With this, PWDs will see the benefits of Afrezza within one or two weeks. [Note that Damon Dash's A1C went from 10 to 7 in one month].
|
|
|
|
Post by agedhippie on Jun 15, 2017 14:29:19 GMT -5
I would be curious about what they measure that lets them tell you your average reading for the last two weeks. My suspicion is that it does the same as a meter - it collects each reading and then averages them rather than giving a two week average from a single test.
BTW. this is a variation on really old tech! Before meters when you had to use urine strips to test there were devices that you inserted the strip into which read the color of the strip and gave you your level.
|
|
|
|
Post by compound26 on Jun 15, 2017 14:36:57 GMT -5
glucemapoc.com/glucemapoc.com/?page_id=1558SALIENT FEATURES OF GLUCEMA TEST Easy to use non-invasive test 2-5 minutes to read from a drop of saliva Test once every 7-14 days Provides quick estimate of recent average glucose levels to monitor treatment
|
|
|
|
Post by harryx1 on Jun 15, 2017 14:37:07 GMT -5
What the what!?!?!??!? Would be interesting to see Afrezza up against those statistics.  I've been looking for those studies but no luck yet finding it/them. * Insulia from Voluntis - the first-ever FDA-cleared prescription basal insulin titration app for type 2 diabetes. Why is this exciting? Well, did you know that studies say 82% of T2 patients discontinue their Lantus or Levemir insulin treatment within 12 months? Insulia's companion app (Android or iOS) provides basal insulin dosing recommendations and educational messages based on blood glucose values for patients, and a web-based portal for doctors where they can configure personalized treatment plans based on the patient’s profile, prescription and BG targets. Insulia has also recently partnered with Livongo Health to bring this dosing support to users of that connected meter.  |
|
|
|
Post by peppy on Jun 15, 2017 14:41:29 GMT -5
What the what!?!?!??!? Would be interesting to see Afrezza up against those statistics. I've been looking for those studies but no luck yet finding it/them. * Insulia from Voluntis - the first-ever FDA-cleared prescription basal insulin titration app for type 2 diabetes. Why is this exciting? Well, did you know that studies say 82% of T2 patients discontinue their Lantus or Levemir insulin treatment within 12 months? Insulia's companion app (Android or iOS) provides basal insulin dosing recommendations and educational messages based on blood glucose values for patients, and a web-based portal for doctors where they can configure personalized treatment plans based on the patient’s profile, prescription and BG targets. Insulia has also recently partnered with Livongo Health to bring this dosing support to users of that connected meter. harry, it did not say why 82% of type two's discontinue their lantus and levemir. Some people, just say no?
|
|
|
|
Post by agedhippie on Jun 15, 2017 17:25:10 GMT -5
glucemapoc.com/glucemapoc.com/?page_id=1558SALIENT FEATURES OF GLUCEMA TEST Easy to use non-invasive test 2-5 minutes to read from a drop of saliva Test once every 7-14 days Provides quick estimate of recent average glucose levels to monitor treatment Ok - I'm sold sign me up, where can I buy it? This looks really useful. I knew that your body dumps excess sugar into your saliva (I can taste when I am high) but I didn't realize it persisted. |
|
|
|
Post by compound26 on Jun 15, 2017 17:27:13 GMT -5
glucemapoc.com/glucemapoc.com/?page_id=1558SALIENT FEATURES OF GLUCEMA TEST Easy to use non-invasive test 2-5 minutes to read from a drop of saliva Test once every 7-14 days Provides quick estimate of recent average glucose levels to monitor treatment Ok - I'm sold sign me up, where can I buy it? This looks really useful. I knew that your body dumps excess sugar into your saliva (I can taste when I am high) but I didn't realize it persisted. Ok, if it's cheap, I might buy one. |
|
|
|
Post by peppy on Jun 15, 2017 17:35:05 GMT -5
let us know what you two think when you try it. Is it useful?
kind of sound like it works a bit like ph paper.
|
|
|
|
Post by compound26 on Jun 15, 2017 17:44:03 GMT -5
let us know what you two think when you try it. Is it useful? kind of sound like it works a bit like ph paper. It's not available yet. Probably sometime in 2018. |
|
|
|
Post by peppy on Jun 15, 2017 19:00:54 GMT -5
let us know what you two think when you try it. Is it useful? kind of sound like it works a bit like ph paper. It's not available yet. Probably sometime in 2018. so is glucowise What is the current status? When will it be available to order?GlucoWise™ is currently in development and will be available to purchase once clinical trials are completed. We expect to start taking pre-orders in late 2018.
last year it said, it would be out late 2017.
(I have to stop posting! They will kill me.)
|
|
